Navigation Links
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
Date:10/15/2008

Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results

published in Journal of Clinical Oncology

SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free survival. A companion editorial discussed the growing evidence for the efficacy of radioimmunotherapy (RIT) in B-cell lymphomas. Cell Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for use of Zevalin in first-line consolidation therapy based on the FIT data.

Oliver W. Press, M.D., Ph.D., Member of the Fred Hutchinson Cancer Research Center and Professor at the University of Washington, commented in his editorial that the studies "confirm and extend prior data demonstrating the tremendous potential of RIT in the treatment of B-cell NHL at diagnosis and after relapse at both conventional and myeloablative doses. Despite the overwhelming body of evidence, however, RIT remains underused in the United States and other countries. The reasons for this underuse have been widely debated but seem to be related, at least partially, to logistic issues involved in the transfer of care from the hematologist/oncologist to the nuclear medicine physician, concerns about inadequate reimbursement by Medicare for RIT, and exaggerated emphasis on delayed effects such as marrow damage and secondary malignancies. It is hoped that studies such as those in this issue would encourage wider appreciation and use of RIT."

"We couldn't agree more with Dr. Press' comments about
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
2. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
3. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
4. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
5. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
6. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
7. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
8. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
9. Hospital Launches Landmark Emergency Medicine Project
10. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
11. Viatronix V3D-Colon Utilized in Another Landmark Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... 20 Escalon Medical Corp...its fiscal first quarter ended September 30, 2009....duct revenue decreased approximately $234,000, or ...ended September 30, 2009 as compared to the same p...decreased net revenue of $8,434,000 compared with ...
(Date:11/20/2009)...Nov. 20 /PRNewswire-FirstCall/ -- Landauer, Inc...e fiscal fourth quarter and full year of 2009 pre-...pany will host a conference call for investors on ...me. Investors may access the live call by dialing ..., or 480-629-9835 (international callers), or by v...
(Date:11/20/2009)...ov. 20 Reportlinker.com announces ...its catalogue. ,, Pipettes & Pipettors - A...ortlinker.com/p0164373/Pipettes--Pipettors---A-Glo...amp;utm_medium=pr&utm_campaign=prnewswire ,...ral part of any research laboratory. Large-scale a...
Breaking Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Swedish American Life Science Summit 28SALSS 29 to Address Major Issues Including Healthcare Reform Synthetic Biology and Innovative Financing for B 13595 1Swedish American Life Science Summit 28SALSS 29 to Address Major Issues Including Healthcare Reform Synthetic Biology and Innovative Financing for B 13595 2Swedish American Life Science Summit 28SALSS 29 to Address Major Issues Including Healthcare Reform Synthetic Biology and Innovative Financing for B 13595 3Swedish American Life Science Summit 28SALSS 29 to Address Major Issues Including Healthcare Reform Synthetic Biology and Innovative Financing for B 13595 4Agency Provides Free Web Site Review 54652 1Agency Provides Free Web Site Review 54652 2Taking up music so you can hear 54647 1Taking up music so you can hear 54647 2Taking up music so you can hear 54647 3
(Date:11/21/2009)...Discusses Key Provisions of Legislation, Continues.... CHARLES, Ill., Nov. 21 /PRNewswire-USNewswire/ -... the landmark Affordable Health Care for America A...eform legislation forward, Congress has taken deci...system. Today, AARP hosted an educational forum t...
(Date:11/21/2009)... HAPPYneuron,s most popular and addictive game, Sp...Touch. , Mountain View, C...popular and addictive game, SplitWords, is now ava...s designed to help banish that ,tip of the tongue,...in game challenges the brain by encouraging users...
(Date:11/20/2009)...rologist Closer to Understanding Brain Wiring and ...ewswire/ -- Dr. Jeremy Schmahmann, Professor of Ne...at the Massachusetts General Hospital in Boston, o...s research on the new field of study called "Conne... ,, Dr. Schmahmann is an award-winning leader i...
(Date:11/20/2009)... Nov. 20 Following a recall by Uni...ved from sale Shedd,s Country Crock ® Side Di...try Crock ® Side Dishes DELUXE Four Cheese Pa...The following code dates and UPCs are affected: ,...XE Cheddar Broccoli Rice 21 oz, UPC 027400218316, ...
(Date:11/20/2009)...Nov. 20 Centene Corpor...present at the Bank of America Merrill Lynch 2009 ...at the Crowne Plaza Hotel Times Square in New York...ber 2nd at 8:30 a.m. Eastern Time. Investors and o...ebcast of Centene,s presentation at: http://www.v...
Breaking Medicine News(10 mins):Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2
...ing sponsor for the All Are Our Heroes song projec... the efforts to overcome cancer. , , ATLANTA, Apr... the science of cancer care, it,s easy to lose sig...spiring song was written to send a message of fait...
...tment will aid ,WFH,s Global Alliance for Progress...world , King of Prussia, ... In recognition of the World Federation of Hemophi...gram, CSL Behring has committed to donating to W...
...mputer technology is making it possible to view th...fore the procedure is performed – and Dr. Ti...taking advantage of it. , ...edure?’ A clear and detailed answer may have...
... -- GfK Asia is pleased to release,its first ever ...ptical,industry today in line with the 14th MAPO (...r 2009. According to our recent survey in Malaysi...e is a steady,demand for contact lenses in Malaysi...
.../ - Further to the press releases of March 31 and ...) (TSX: BLU) is pleased to announce the completion...Cdn. $20.5 million financing. , BELLUS Health rece...5 million from Victoria Square Ventures Inc.) and ...
...n as an idea to fight airborne germs and bacteria ... Accents in Water remains the only Hospital-Approv...the world today. Then, general public settings lik...manded these particular water features for their h...
Other Medicine News:Health News:Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness 2Health News:Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness 3Health News:CSL Behring Marks World Hemophilia Day with $2M Coagulation Factor Donation to World Federation of Hemophilia 2Health News:CSL Behring Marks World Hemophilia Day with $2M Coagulation Factor Donation to World Federation of Hemophilia 3Health News:CSL Behring Marks World Hemophilia Day with $2M Coagulation Factor Donation to World Federation of Hemophilia 4Health News:Nevada Breast Augmentation Surgeon Gives Reno Patients a Glimpse of Likely Results with Portrait 3D Computer Imagery 2Health News:Nevada Breast Augmentation Surgeon Gives Reno Patients a Glimpse of Likely Results with Portrait 3D Computer Imagery 3Health News:GfK Asia Releases First Ever Malaysian Contact Lens Industry Retail Measurement 2Health News:GfK Asia Releases First Ever Malaysian Contact Lens Industry Retail Measurement 3Health News:BELLUS Health inc. announces completion of first tranche of financing 2Health News:Hospital Approved Residential Water Features Kill Harmful Airborne Bacteria 2
FirstChoice Urostomy Pouches, Convex
FirstChoice Urostomy Kit
FirstChoice Drainable Pouches
FirstChoice Closed Pouch, SoftFlex, Cut-to-fit
Medicine Products: